scholarly journals Maternal obesity impairs brain glucose metabolism and neural response to hyperglycemia in male rat offspring

2013 ◽  
Vol 129 (2) ◽  
pp. 297-303 ◽  
Author(s):  
Hui Chen ◽  
David Simar ◽  
Margaret J. Morris
Keyword(s):  
Glucose Metabolism ◽  
Maternal Obesity ◽  
Neural Response ◽  
Male Rat ◽  
Brain Glucose ◽  
Brain Glucose Metabolism ◽  
Rat Offspring

scholarly journals The impact of a multi-domain intervention on cerebral glucose metabolism: analysis from the randomized ancillary FDG PET MAPT trial

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Julien Delrieu ◽  
Thierry Voisin ◽  
Laure Saint-Aubert ◽  
Isabelle Carrie ◽  
Christelle Cantet ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Fdg Pet ◽  
Primary Outcome ◽  
Cognitive Stimulation ◽  
Cerebral Glucose Metabolism ◽  
Parahippocampal Gyrus ◽  
Cerebral Magnetic Resonance Imaging ◽  
Brain Glucose ◽  
Brain Glucose Metabolism ◽  
The Impact

Abstract Background The Multidomain Alzheimer Preventive Trial (MAPT) was designed to assess the efficacy of omega-3 fatty acid supplementation, multidomain intervention (MI), or a combination of both on cognition. Although the MAPT study was negative, an effect of MI in maintaining cognitive functions compared to placebo group was showed in positive amyloid subjects. A FDG PET study (MAPT-NI) was implemented to test the impact of MI on brain glucose metabolism. Methods MAPT-NI was a randomized, controlled parallel-group single-center study, exploring the effect of MI on brain glucose metabolism. Participants were non-demented and had memory complaints, limitation in one instrumental activity of daily living, or slow gait. Participants were randomly assigned (1:1) to “MI group” or “No MI group.” The MI consisted of group sessions focusing on 3 domains: cognitive stimulation, physical activity, nutrition, and a preventive consultation. [18F]FDG PET scans were performed at baseline, 6 months, and 12 months, and cerebral magnetic resonance imaging scans at baseline. The primary objective was to evaluate the MI effect on brain glucose metabolism assessed by [18F]FDG PET imaging at 6 months. The primary outcome was the quantification of regional metabolism rate for glucose in cerebral regions involved early in Alzheimer disease by relative semi-quantitative SUVr (FDG-based AD biomarker). An exploratory voxel-wise analysis was performed to assess the effect of MI on brain glucose metabolism without anatomical hypothesis. Results The intention-to-treat population included 67 subjects (34 in the MI group and 33 in the No MI group. No significant MI effect was observed on primary outcome at 6 months. In the exploratory voxel-wise analysis, we observed a difference in favor of MI group on the change of cerebral glucose metabolism in limbic lobe (right hippocampus, right posterior cingulate, left posterior parahippocampal gyrus) at 6 months. Conclusions MI failed to show an effect on metabolism in FDG-based AD biomarker, but exploratory analysis suggested positive effect on limbic system metabolism. This finding could suggest a delay effect of MI on AD progression. Trial registration ClinicalTrials.gov Identifier, NCT01513252.

scholarly journals Highly palatable diet changes brain glucose metabolism in mice

2020 ◽  
Vol 16 (S10) ◽  
Author(s):  
Sarah Wehle Gehres ◽  
Andreia Silva da Rocha ◽  
Yuri Elias Rodrigues ◽  
Guilherme G Schu Peixoto ◽  
Afonso Kopczynski Carvalho ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Brain Glucose ◽  
Brain Glucose Metabolism ◽  
Palatable Diet ◽  
Highly Palatable Diet

scholarly journals Brain Glucose Metabolism in Health, Obesity, and Cognitive Decline—Does Insulin Have Anything to Do with It? A Narrative Review

2021 ◽  
Vol 10 (7) ◽  
pp. 1532
Author(s):  
Eleni Rebelos ◽  
Juha O. Rinne ◽  
Pirjo Nuutila ◽  
Laura L. Ekblad
Keyword(s):  
Insulin Resistance ◽  
Glucose Metabolism ◽  
Cognitive Decline ◽  
Fdg Pet ◽  
Metabolic Disorders ◽  
Brain Glucose ◽  
Brain Glucose Metabolism ◽  
Systemic Insulin Resistance ◽  
Increased Risk ◽  
18F Fdg

Imaging brain glucose metabolism with fluorine-labelled fluorodeoxyglucose ([18F]-FDG) positron emission tomography (PET) has long been utilized to aid the diagnosis of memory disorders, in particular in differentiating Alzheimer’s disease (AD) from other neurological conditions causing cognitive decline. The interest for studying brain glucose metabolism in the context of metabolic disorders has arisen more recently. Obesity and type 2 diabetes—two diseases characterized by systemic insulin resistance—are associated with an increased risk for AD. Along with the well-defined patterns of fasting [18F]-FDG-PET changes that occur in AD, recent evidence has shown alterations in fasting and insulin-stimulated brain glucose metabolism also in obesity and systemic insulin resistance. Thus, it is important to clarify whether changes in brain glucose metabolism are just an epiphenomenon of the pathophysiology of the metabolic and neurologic disorders, or a crucial determinant of their pathophysiologic cascade. In this review, we discuss the current knowledge regarding alterations in brain glucose metabolism, studied with [18F]-FDG-PET from metabolic disorders to AD, with a special focus on how manipulation of insulin levels affects brain glucose metabolism in health and in systemic insulin resistance. A better understanding of alterations in brain glucose metabolism in health, obesity, and neurodegeneration, and the relationships between insulin resistance and central nervous system glucose metabolism may be an important step for the battle against metabolic and cognitive disorders.

Brain glucose metabolism in neuropathologically confirmed multiple system atrophy

2013 ◽  
Vol 260 (7) ◽  
pp. 1922-1924 ◽  
Author(s):  
Valtteri Kaasinen ◽  
Maria Gardberg ◽  
Marko Seppänen ◽  
Matias Röyttä ◽  
Riitta Parkkola ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Multiple System Atrophy ◽  
Brain Glucose ◽  
Brain Glucose Metabolism
Sign in / Sign up

Export Citation Format

Share Document